ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 24, 2005

SAN DIEGO, Feb 17, 2005 /PRNewswire-FirstCall via COMTEX/ — ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the BIO CEO & Investor Conference on Thursday, February 24, 2005, at 2:30 pm Eastern Time at the Waldorf=Astoria Hotel in New York City.

A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through March 10, 2005.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson’s disease, neuropathic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA’s corporate headquarters and biology research facilities are located in San Diego, California and its chemistry research facilities are located near Copenhagen, Denmark.

For further information, please contact Lisa Barthelemy, Director of Investor Relations, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558-2871, ir@acadia-pharm.com.

Lisa Barthelemy, Director of Investor Relations, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558-2871, ir@acadia-pharm.com